Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC) — Josep M. Llovet (2016) | RDL Network
Ho Yeong Lim, Philippe Merle, Karl Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Katrin Roth, Diego Reis, Barrett H. Childs, Heiko Krissel, Josep M. Llovet
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Cheng‐Chen Chang, Yang Kang, Éric Assenat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Derek Lin, Jordi Bruix, Rtp Poon, Morris Sherman, J.-F. Blanc, Richard S. Finn, Won Young Tak, You‐Chen Chao, Rana Ezzeddine, D. Liu,
Josep M. Llovet, María Isabel Real, R. Vilana, Ramón Planas, S. Coll, John J. Aponte, Carmen Ayuso, María Sala, Jordi Muchart, R. Costa, J Rodés, Jordi Bruix
Discussion(0)
No comments yet. Be the first to comment.